Skeletal Muscle Protein Synthetic Response to Amino Acid and Peptides

Protein Metabolism Clinical Trial

Official title:

Skeletal Muscle Protein Synthetic Response to Amino Acid and Peptides

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03952884
• Other study ID #: 18897
• Status: Completed
• Phase: N/A
• Start date: May 3, 2019
• Est. completion date: November 20, 2019

Study information

• Verified date: September 2020
• Source: University of Illinois at Urbana-Champaign
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Skeletal muscle quality is an important determinant of exercise performance and overall health. It is vital for not just movement, but also metabolizing nutrients. Protein from the diet can promote muscle protein synthesis for muscle recovery and growth. More importantly, doing so shifts net protein balance positively (e.g. protein synthesis is greater than protein breakdown) and promotes greater rates of muscle protein turnover. Leucine is an amino acid required to build muscle, but it also acts as a signaling molecule informing the muscle to start protein synthesis. Before reaching skeletal muscle, dietary protein is digested into small peptides and free amino acids. Rate of absorption from the intestine to the blood stream is significantly faster for peptides compared to amino acids. As amino acid availability in the blood is a precursor for muscle protein synthesis, our objective is to determine if the different absorption rates between free amino acid and peptides influence muscle protein synthetic and breakdown rates.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: November 20, 2019
• Est. primary completion date: November 20, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 35 Years

Eligibility

Inclusion Criteria:

• Recreationally-active adults: = 30 min of physical activity at moderate intensity = 3 times per week

• Ages: 18-35 years old

• English fluency

Exclusion Criteria:

• Tobacco, nicotine (patch/gum) use (previous 6 mo)

• Alcohol consumption >10 drinks per week

• Metabolic disorders (e.g., Metabolic Syndrome, Diabetes, thyroid diseases)

• Cardiovascular disease, arrhythmias

• Hypogonadism

• Asthma

• History of uncontrolled hypertension

• Orthopedic injury/surgery (within 1 yr)

• Hepatorenal, musculoskeletal, autoimmune, or neurological disease

• History of neuromuscular problems

• Previous participation in amino acid tracer studies

• Predisposition to hypertrophic scarring or keloid formation

• Consumption of ergogenic-levels of dietary supplements that may affect muscle mass (e.g., creatine, HMB), insulin-like substances, or anabolic/catabolic pro-hormones (e.g., DHEA) within 6 weeks prior to participation

• Consumption of thyroid, androgenic, or other medications known to affect endocrine function

• Consumption of medications known to affect protein metabolism (e.g., prescription-strength corticosteroids, non-steroidal anti-inflammatories, or acne medication)

• Currently pregnant

Related Conditions & MeSH terms

• Protein Metabolism

Intervention

Behavioral:
• Resistance Exercise
Prior to protein consumption participants will perform an acute bout of resistance exercise. They will warm up with two sets of 10 repetitions at 35-75% working load respectively, then perform four working sets of 10-12 repetitions at 65-70% of 1-RM. 1 min, 30 sec rest periods will be implemented between each set.
• No Resistance Exercise
Participants allocated to this group will not perform exercise prior to the administration of the nutritional intervention. Participants will remain at rest throughout the trial.

Dietary Supplement:
• Leucine
Participants will be given 2g of leucine dissolved in 250mL of water. Drink will be consumed immediately after exercise or equivalent time point for non-exercise group.
• Dileucine
Participants will be given 2g of dileucine dissolved in 250mL of water. Drink will be consumed immediately after exercise or equivalent time point for non-exercise group.

Locations

Country	Name	City	State
United States	Freer Hall	Urbana	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
University of Illinois at Urbana-Champaign

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fractional Synthetic Rate of Mixed Muscle Proteins	Mixed muscle protein synthesis rates will be assessed during the 3.5hr Postabsorptive period (e.g. non-fed state) and the 3hr postprandial period (e.g. fed state) for both experimental interventions (e.g. leucine and leucine peptide). This will allow us to assess the change in fractional synthetic rate from the Postabsorptive period to the postprandial period.	Postabsorptive for 3.5 hours, Postprandial for 3 hours.
Primary	Fractional Synthetic Rate of Myofibrillar Proteins	Myofibrillar muscle protein synthesis rates will be assessed during the 3.5hr Postabsorptive period (e.g. non-fed state) and the 3hr postprandial period (e.g. fed state) for both experimental interventions (e.g. leucine and leucine peptide). This will allow us to assess the change in fractional synthetic rate from the Postabsorptive period to the postprandial period.	Postabsorptive for 3.5 hours, Postprandial for 3 hours.
Primary	Fractional Breakdown Rate of Mixed Muscle Proteins	Mixed muscle protein breakdown rates will be assessed during the first hour of the postprandial period (e.g. fed state) for both experimental interventions (e.g. leucine and leucine peptide). This will allow us to assess the change in fractional breakdown rate for each respective experimental intervention.	Postprandial for 1 hour
Secondary	Phosphorylation of muscle anabolic signaling	Phosphorylation of anabolic signaling pathways will be assessed in the fasted state and after the ingestion of the experimental interventions.	Baseline, immediately after ingestion of leucine/leucine peptides, and 3 hours after ingestion of leucine/leucine peptides